11 Things That Are Still Told to Menopausal Women in Clinic That the Evidence Has Contradicted
Sitting in a consulting room and being told something that doesn't feel right is one of the most disorienting experiences in perimenopause. So many women describe leaving appointments with a prescription for antidepressants when they went in asking about hormones, or being told to 'come back when things are worse.' Knowing what the evidence actually says doesn't make you difficult — it makes you informed. And you deserve to be informed.
Learn more about Rose →"You should only take HRT for five years maximum"
The five-year limit originates from a misreading of the 2002 Women's Health Initiative study, which used older synthetic hormones at doses and in populations that don't reflect current prescribing practice. The British Menopause Society, NICE, and the Menopause Society all now state there is no arbitrary time limit on HRT use — duration should be based on individual benefit-risk assessment reviewed regularly. Many women use HRT safely for a decade or more, particularly when started during the window of opportunity around menopause.
"HRT significantly increases your risk of breast cancer"
The absolute risk associated with combined HRT is small and context-dependent — for most women under 60 using body-identical progesterone, the increased risk is comparable to drinking one glass of wine per day or being overweight. Estrogen-only HRT, used by women who have had a hysterectomy, is associated with either a neutral or slightly reduced breast cancer risk in most analyses. The 2019 Lancet meta-analysis that caused widespread alarm has since been scrutinised for conflating different progestogen types, and body-identical micronised progesterone appears to carry a substantially lower risk than older synthetic progestogens.
"Your symptoms should resolve within a year of your last period"
Population data consistently shows that vasomotor symptoms — hot flushes and night sweats — persist for a median of seven to ten years after the final menstrual period, not one. The SWAN study followed women longitudinally and found that around a third of women experience symptoms for more than a decade. Telling women their symptoms are almost over when they may have years ahead of them delays treatment decisions and causes unnecessary distress.
"Antidepressants are a first-line treatment for menopause symptoms"
Antidepressants are not licensed for menopausal symptom management in most countries, and NICE guidelines are explicit that they should not be offered as a first-line treatment for vasomotor symptoms in women without a comorbid mood disorder. They have a modest evidence base for hot flush reduction specifically, but perform significantly less well than HRT, and do not address the underlying hormonal cause. Women without clinical depression who are prescribed SSRIs or SNRIs for menopause symptoms are receiving off-label treatment that bypasses the more effective option.
"HRT is not safe if you have migraines"
Migraine with aura does increase stroke risk and is a contraindication to the combined oral contraceptive pill — but transdermal HRT is a different matter entirely. Transdermal estrogen (patches, gels, sprays) does not increase clotting risk because it bypasses first-pass liver metabolism and does not raise inflammatory markers. Current guidance from headache and menopause specialists is that transdermal HRT is generally safe for women with migraine, including migraine with aura, and may actually reduce migraine frequency in some women by stabilising estrogen fluctuations.
"HRT is not appropriate if you have a family history of breast cancer"
A family history of breast cancer is not an automatic contraindication to HRT — this conflates familial risk with personal risk. NICE guidelines and most specialist menopause societies state that a family history alone should not preclude HRT, and that the decision should involve a careful individual risk assessment. For women with BRCA mutations or a significant family history, this conversation should ideally involve a specialist, but a maternal aunt with breast cancer diagnosed at 70 is categorically different from a BRCA1 carrier and should not receive the same blanket refusal.
"Brain fog and memory problems are just anxiety — not a menopause symptom"
Cognitive symptoms including word-finding difficulties, working memory lapses, and mental fogginess are well-documented features of perimenopause and menopause with a plausible neurobiological mechanism: estrogen receptors are distributed throughout the brain, including in regions governing memory and executive function. Research from the Study of Women's Health Across the Nation (SWAN) confirmed objective cognitive changes during the menopausal transition. Dismissing these symptoms as anxiety not only misses the cause but can lead to unnecessary psychiatric referrals and delayed hormonal assessment.
"HRT causes blood clots, so it's not safe"
Oral estrogen does carry an increased risk of venous thromboembolism (VTE) because tablets are metabolised through the liver, triggering clotting factor changes. However, transdermal estrogen — delivered via skin patches, gels, or sprays — does not carry this increased risk, as confirmed by multiple observational studies and the ESTHER study specifically. Women who are told HRT causes blood clots without being offered the transdermal route are being given incomplete and potentially risk-distorting information.
"Genitourinary symptoms are just dryness — use a lubricant and you'll be fine"
Genitourinary syndrome of menopause (GSM) encompasses not just vaginal dryness but also thinning of urethral and vaginal tissue, increased UTI frequency, urinary urgency, and painful intercourse — a constellation of changes that worsen progressively without treatment. Unlike vasomotor symptoms, GSM does not resolve over time; it typically advances. Vaginal lubricants help with comfort during intercourse but do not reverse the underlying tissue atrophy, whereas local vaginal estrogen does — and with negligible systemic absorption, it is safe for the vast majority of women including most breast cancer survivors.
"You're too young to be in perimenopause at 40"
Perimenopause can begin years before the final menstrual period and commonly starts in the early-to-mid 40s, with hormonal fluctuations driving symptoms well before periods become irregular. The average age of the final menstrual period in the UK is 51, but perimenopausal symptoms often emerge from the mid-40s onward — meaning a symptomatic 43-year-old is entirely within the expected range. Dismissing younger women solely on the basis of age delays diagnosis, leaves symptoms unmanaged, and means women lose the bone density and cardiovascular protective benefits that earlier treatment could provide.
"You don't need a testosterone test — testosterone isn't for women"
Testosterone is produced naturally in women's ovaries and adrenal glands and plays a documented role in libido, energy, mood, and cognitive function — levels decline significantly across the menopausal transition. The British Menopause Society and the Global Consensus Position Statement both recognise testosterone therapy as evidence-based for hypoactive sexual desire disorder (HSDD) in menopausal women. Routine dismissal of women asking about testosterone — often based on the misconception that it is exclusively a male hormone — denies access to a therapy with a meaningful evidence base and a good safety profile at physiological doses.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.